EORTC 62012 was a phase 3 randomised trial in advanced or metastatic high-grade soft-tissue sarcoma. It compared first-line doxorubicin alone against intensified doxorubicin plus ifosfamide across 38 hospitals in 10 countries. The trial asked whether adding ifosfamide, and its added toxicity, improves overall survival.
When counseling a patient on first-line chemotherapy for advanced soft-tissue sarcoma, the decision rule is straightforward: match the regimen to the goal. If the aim is pure palliation and survival, single-agent doxorubicin is appropriate. It is less toxic and does not shorten survival.
If the aim is tumour shrinkage, to relieve acute symptoms, downstage before surgery or radiotherapy, or protect an adjacent critical structure, the doxorubicin-ifosfamide combination is justified because it nearly doubles response rate and adds 2·8 months of progression-free survival.
The key teaching point is separating endpoints. Better response and PFS do not automatically mean better survival, and the combination carries a heavy toxicity price (46% febrile neutropenia).
This trial stands out because it was uniquely powered for overall survival, unlike most prior dose-intensification studies that were response-driven. Note the age ceiling of 60 years means these data cannot be extrapolated to older patients.
EORTC 62012 was a phase 3 randomised trial in advanced or metastatic high-grade soft-tissue sarcoma. It compared first-line doxorubicin alone against intensified doxorubicin plus ifosfamide across 38 hospitals in 10 countries. The trial asked whether adding ifosfamide, and its added toxicity, improves overall survival.
When counseling a patient on first-line chemotherapy for advanced soft-tissue sarcoma, the decision rule is straightforward: match the regimen to the goal. If the aim is pure palliation and survival, single-agent doxorubicin is appropriate. It is less toxic and does not shorten survival.
If the aim is tumour shrinkage, to relieve acute symptoms, downstage before surgery or radiotherapy, or protect an adjacent critical structure, the doxorubicin-ifosfamide combination is justified because it nearly doubles response rate and adds 2·8 months of progression-free survival.
The key teaching point is separating endpoints. Better response and PFS do not automatically mean better survival, and the combination carries a heavy toxicity price (46% febrile neutropenia).
This trial stands out because it was uniquely powered for overall survival, unlike most prior dose-intensification studies that were response-driven. Note the age ceiling of 60 years means these data cannot be extrapolated to older patients.